NASDAQ:CFMSConforMIS Stock Price, Forecast & News

$0.60

-0.05 (-7.26 %)

(As of 04/7/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.58

Now: $0.60▼

$0.66

50-Day Range

$0.56

MA: $0.77▼

$1.12

52-Week Range

$0.50

Now: $0.60▼

$4.83

Volume27,118 shs

Average Volume576,686 shs

Market Capitalization$43.14 million

P/E RatioN/A

Dividend YieldN/A

Beta2.08

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
ConforMIS has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, ConforMIS has a potential upside of 397.7% from its current price of $0.60.
Amount of Analyst Coverage
ConforMIS has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
ConforMIS has received 337 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ConforMIS has received 280 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ConforMIS has received 54.62% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote “Outperform” if you believe CFMS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ConforMIS does not currently pay a dividend.
Dividend Growth
ConforMIS does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ConforMIS insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.19% of the stock of ConforMIS is held by insiders.
Percentage Held by Institutions
40.14% of the stock of ConforMIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for ConforMIS are expected to decrease by -21.05% in the coming year, from ($0.38) to ($0.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ConforMIS is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ConforMIS is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ConforMIS has a P/B Ratio of 2.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.41 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical appliances & supplies

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CFMS

Previous Symbol

CUSIPN/A

CIK1305773

Webhttp://www.conformis.com/

Phone781-345-9001

Debt

Debt-to-Equity Ratio2.24

Current Ratio2.94

Quick Ratio2.26

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$77.43 million

Price / Sales0.56

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.24 per share

Price / Book2.51

Profitability

EPS (Most Recent Fiscal Year)($0.44)

Net Income$-28,480,000.00

Net Margins-36.78%

Return on Equity-121.27%

Return on Assets-41.44%

Miscellaneous

Employees262

Outstanding Shares71,560,000

Market Cap$43.14 million

Next Earnings Date5/6/2020 (Estimated)

OptionableNot Optionable

Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter.

ConforMIS (NASDAQ:CFMS) Frequently Asked Questions

How has ConforMIS's stock been impacted by COVID-19 (Coronavirus)?

ConforMIS's stock was trading at $0.66 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CFMS stock has decreased by 8.7% and is now trading at $0.6028. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ConforMIS?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ConforMIS.

When is ConforMIS's next earnings date?

ConforMIS is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for ConforMIS.

How were ConforMIS's earnings last quarter?

ConforMIS Inc (NASDAQ:CFMS) announced its quarterly earnings data on Monday, March, 2nd. The medical instruments supplier reported ($0.08) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.10) by $0.02. The medical instruments supplier had revenue of $19.89 million for the quarter, compared to analysts' expectations of $19.91 million. ConforMIS had a negative net margin of 36.78% and a negative return on equity of 121.27%. View ConforMIS's earnings history.

What guidance has ConforMIS issued on next quarter's earnings?

ConforMIS updated its fourth quarter 2019 Pre-Market earnings guidance on Tuesday, January, 14th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.9-19.9 million, compared to the consensus revenue estimate of $20.21 million.

What price target have analysts set for CFMS?

3 brokers have issued 1 year price targets for ConforMIS's shares. Their forecasts range from $2.00 to $4.00. On average, they anticipate ConforMIS's share price to reach $3.00 in the next year. This suggests a possible upside of 397.7% from the stock's current price. View analysts' price targets for ConforMIS.

What are Wall Street analysts saying about ConforMIS stock?

Here are some recent quotes from research analysts about ConforMIS stock:

1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (3/31/2020)
2. BTIG Research analysts commented, "$3 PT on Improving Trends We maintain our Buy rating and $3 PT following 1Q19 results which came in slightly ahead of expectations. Revenue of $20.6M compared favorably to BTIG/Street estimates of $20.0M/$20.1M. Noticeably CFMS saw encouraging uptake with both iTotal PS (+29% xFx) and iTotal Hip (still in the early stages of launch). GMs continued their upward trajectory, increasing 290 bps Y/Y to 47.6%. We believe CFMS’s worst days are behind it and the company is entering into a phase of improved and steady LSD growth driven by existing and recently launched products which give a growing distributor base a full recon line to sell. Recon surgery is clearly moving rapidly towards robotics but CFMS is going against the grain with an alternative option that may appeal to a group of surgeons who don’t want to be tied to a robotic system." (5/2/2019)

Has ConforMIS been receiving favorable news coverage?

News articles about CFMS stock have been trending very negative on Tuesday, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ConforMIS earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutConforMIS.

Are investors shorting ConforMIS?

ConforMIS saw a increase in short interest in February. As of February 28th, there was short interest totaling 4,010,000 shares, an increase of 21.5% from the February 13th total of 3,300,000 shares. Based on an average daily volume of 616,800 shares, the short-interest ratio is presently 6.5 days. Approximately 6.2% of the shares of the company are short sold. View ConforMIS's Current Options Chain.

Who are some of ConforMIS's key competitors?

Some companies that are related to ConforMIS include Lakeland Industries (LAKE), RTI Surgical (RTIX), Sientra (SIEN), Allied Healthcare Products (AHPI), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), NanoVibronix (NAOV), Bionik Laboratories (BNKL), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), Ocugen (OCGN) and Avitar (AVTI).

What other stocks do shareholders of ConforMIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ConforMIS investors own include Martin Midstream Partners (MMLP), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Cisco Systems (CSCO), AT&T (T), Alibaba Group (BABA), Pfizer (PFE), Intel (INTC) and Starbucks (SBUX).

Who are ConforMIS's key executives?

ConforMIS's management team includes the following people:

Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
Mr. Ed Kilgallen, VP of Operations
Ms. Lisa M. Donnelly, Sr. VP of Global Marketing

When did ConforMIS IPO?

(CFMS) raised $135 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is ConforMIS's stock symbol?

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

How do I buy shares of ConforMIS?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ConforMIS's stock price today?

One share of CFMS stock can currently be purchased for approximately $0.60.

How big of a company is ConforMIS?

ConforMIS has a market capitalization of $43.14 million and generates $77.43 million in revenue each year. The medical instruments supplier earns $-28,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. ConforMIS employs 262 workers across the globe. View additional information about ConforMIS.

What is ConforMIS's official website?

The official website for ConforMIS is http://www.conformis.com/.

How can I contact ConforMIS?

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

NASDAQ:CFMSConforMIS Stock Price, Forecast & News

Adding

Adding

Adding ConforMIS Inc

Beat the Market (BTM) Rank™

3.3 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage